1 / 7

3 D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-I

Phase 2. HIV Coinfection. Treatment Naïve and Treatment Experienced. 3 D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-I. Wyles D, et al. 65 th AASLD. 2014: Abstract 1939. 3D + Ribavirin for HCV -HIV Coinfection and GT1 TURQUOISE -I: Part 1 Study Design.

moses-zamora
Download Presentation

3 D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 HIV Coinfection Treatment Naïve and Treatment Experienced 3D (Paritaprevir-Ritonavir-Ombitasvir+ Dasabuvir) + RBV in GT1 TURQUOISE-I Wyles D, et al. 65th AASLD. 2014: Abstract 1939.

  2. 3D + Ribavirin for HCV-HIV Coinfectionand GT1TURQUOISE-I: Part 1 Study Design Source: Wyles D, et al. 65th AASLD. 2014: Abstract 1939.

  3. 3D + Ribavirin for HCV-HIV Coinfectionand GT1TURQUOISE-I: Part 1 Study Regimens 0 12 24 36 Week 3D + Ribavirin N = 31 SVR12 3D + Ribavirin N = 32 SVR12 3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Wyles D, et al. 65th AASLD. 2014: Abstract 1939.

  4. 3D + Ribavirin for HCV-HIV Coinfectionand GT 1TURQUOISE-I: Patient Population Source: Wyles D, et al. 65th AASLD. 2014: Abstract 1939.

  5. 3D + Ribavirin for HCV-HIV Coinfectionand GT 1TURQUOISE-I: Part 1 Results TURQUOISE-I: SVR Rates (to date) 29/31 30/32 29/31 29/32 3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Source: Wyles D, et al. 65th AASLD. 2014: Abstract 1939.

  6. 3D + Ribavirin for HCV-HIV Coinfectionand GT 1TURQUOISE-I: Part 1 Results Details of Five Patients NOT Achieving SVR 12 • One patient in 12-week arm withdrew consent prior to finishing treatment; had undetectable HCV RNA at week 10 • One patient in 12-week arm had virologic relapse at week 4 post treatment; had new resistant HCV variants at 3 viral targets (D168V in NS3/4A, M28T in NS5A, and S556G in NS5B) • One patient in 24-week arm had virologic breakthrough during treatment; had new resistant HCV variants at 3 viral targets (R155K in NS3/4A, Q30R in NS5A, and S556G in NS5B) • Two patients in 24-week arm achieved early SVR but appeared to be reinfected with GT1a isolate distinct from baseline HCV isolate; both patients had engaged in high-risk sexual activity post treatment 29/31 30/32 29/31 29/32 Source: Wyles D, et al. 65th AASLD. 2014: Abstract 1939.

  7. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related